Hyphens Pharma has been awarded exclusive rights by MC2 Therapeutics to commercialise and supply Wynzora® Cream and all future product extensions throughout ASEAN. Wynzora® Cream is a leading topical treatment for plaque and scalp psoriasis in adults, currently marketed in Italy, Germany, Spain, United Kingdom and United States. Read more here.
February 2024 – In partnership with Cooper Pharma, Hyphens Pharma’s flagship dermatological brand, Ceradan®, is poised to bring relief to eczema suffers in the Middle East, including Saudi Arabia, United Arab Emirates, Kuwait, Qatar and Bahrain. Click here to read the full story.
Feb & Aug 2023 – We are pleased to bring Nabota® to Malaysian and Singapore markets. A premium high-purity botulinum toxin A (BTA) formulated from our partner Daewoong Pharmaceutical’s patented Hi-PureTM technology, Nabota® is characterised by its high safety, rapid effect, and uniform spreading power. It is the first Asian BTA approved by the U.S. Food and Drug Administration, with over 1 million treatments performed in the United States since 2019.
Developed jointly with Singapore’s Agency for Science, Technology and Research (A*STAR), Meradan® is available through prescription through doctors, dermatologists and paediatricians. Formulated from a patented microemulsion technology, Meradan® treats skin diseases that cause inflammation and itch, such as conditions like eczema, psoriasis, and skin rash. For more details, read the media release here.
TDF® Blu Voile Sunscreen also offers thorough and complete protection against UV-A/UV-B and blue light, versus conventional broad-spectrum sunscreens.(1)
Click here to read our media release for more details.
(1) Francois-Newton V, et al. Int J Cosmet Sci. 2022 Aug;44(4):464-476
The proposed Ustekinumab biosimilar, which is undergoing clinical studies, is a human monoclonal antibody that targets interleukin-12 (“IL-12”) and interleukin-23 (“IL-23”) for the treatment of immune mediated disorders like plaque psoriasis, psoriatic arthritis and Crohn’s disease.
Click here to read our media release for more details.
Fairence® is a a scientifically designed pigment lightening cream enhanced by Xcelarev®, a patented delivery system incorporating three key ingredients, namely Tranexamic acid, Niacinamide and Lactobionic acid, to tackle pigmentation issues such as melasma. Click here to read our media release for more details.
Under this partnership, they will be granted exclusive rights to distribute Ceradan® products, such as Ceradan® Skin Barrier Repair Cream, with the exception of Ceradan® Advanced. Click here to read our media release for more details.
CG 210 is a globally renowned and patented topical botanical hair growth-promoting agent based on Allium cepa (Onion), Citrus medica limonum (lemon), Theobroma cacao (cocoa) and Paullinia cupana (guarana) that works via unique mechanisms of action. Its safety and efficacy have been demonstrated in more than 10 clinical studies involving close to 800 subjects with several publications.
Click here to read our media release for more details.
Ceradan® Advanced is a patented next-generation emollient therapy that is scientifically formulated for eczema-prone skin conditions. Ceradan® Advanced sustainably lowers the skin pH for up to 12 hours to induce skin lipids production and suppresses skin cell breakdown. This helps to accelerate optimal skin barrier repair and restoration.
Click here to read our media release for more details.
MAGNEZIX® is a magnesium alloy metallic implant that can be reabsorbed by the body. Unlike common metal implants, patients now can have a quicker and safer recovery, as they do not need to undergo another surgical intervention to remove such implants. Click here to read our media release for more details.
We are delighted to be able to forge a collaboration with Lundbeck, a globally renowned player in the pharmaceutical domain. Through this exclusive partnership, we will be bringing world class healthcare treatments to the Vietnamese public. Click here to read our media release for more details.
Our collaboration with A*STAR through the MoU with A*ccelerate is a reflection of our commitment to grow through innovation. Click here to read our media release for more details.
By leveraging on A*STAR’s research and development capabilities, we envisioned this will enable us to develop innovative and differentiated dermatological products to address unmet market needs. Dermatology is a key therapeutic focus field for Hyphens and we are encouraged to have A*STAR as our strategic dialogue partner.